Perrigo (PRGO) Q3 2026 Earnings Call Transcript

Perrigo’s Q3 2026 core net sales fell 1.7% year over year to $908 million, core adjusted EPS declined 9% to $0.61, and core adjusted operating margin contracted 210 bps to 14.3%; all-in sales were down 5.2% to $989 million. Management lowered its 2026 outlook, forecasting core reported sales down 2.5%-3.6% and core adjusted EPS of $2.15-$2.35, citing cautious retailer inventory positioning and European consumer softness. Perrigo agreed to divest its infant formula business for up to $175 million, including $40 million upfront, and said the move removes approximately $240 million of previously planned capital expenditures; its cost program generated $42 million in savings year to date.

Analysis

The key risk is earnings quality, not just the sales slowdown: a 3.5% quarterly tax rate contributed about $0.10 to core EPS, masking weaker operating profit. As the rate normalizes, even modest sales stabilization may not translate into comparable EPS recovery. Retailers’ cautious seasonal buying also shifts risk toward timing: a cold-season pickup could produce replenishment, but sales may land in Q1 rather than Q4, while persistently lean inventories would leave Perrigo absorbing demand and utilization volatility.

The infant-formula exit simplifies the portfolio, but the $40 million upfront cash is modest against $3.3 billion of debt; contingent milestones are not equivalent to committed proceeds. The more meaningful potential benefit is avoiding planned network capital spending. Whether that creates value depends on reinvestment discipline: stronger e-commerce exposure and store-brand share gains are promising, but incremental digital growth may require demand-generation spending, and lower contract volumes signal exposure to customer sourcing and utilization decisions. Retailers, meanwhile, gain bargaining leverage when private-label suppliers compete for shelf space.

Near term, the seasonal inventory read-through and Q4/Q1 shipment timing dominate. Over 1–3 months, watch sell-through versus shipments, European category trends, and guidance delivery. Over 6–18 months, deleveraging, normalized tax expense, and whether cost savings offset promotional investment will determine if simplification yields durable EPS growth. The contrarian upside is that retailer caution may be delayed replenishment rather than lost consumption; share gains and service improvements could position Perrigo to capture it. That thesis fails if sell-through weakens or margin recovery stalls.

Key Decisions for Investors

• Maintain an underweight in PRGO versus a broad consumer-staples exposure; avoid adding on sequential-improvement claims alone. Reassess if reported sell-through converts into replenishment and core operating margin sustains improvement without relying on tax benefits.
• Treat seasonal recovery as a timing alert, not a base-case Q4 catalyst. Track retailer orders and channel inventory through Q4 and Q1; delayed replenishment could support next-quarter sales, while continued conservative ordering would falsify the recovery thesis.
• Do not capitalize the full infant-formula milestone consideration or assume the avoided capital spending automatically improves returns. Verify closing terms, cash proceeds, debt application, and subsequent core investment returns.
• Monitor cash generation and leverage alongside earnings: approximately 4x targeted year-end net leverage leaves limited room for execution misses. A dividend-policy change, weaker operating cash flow, or failure to reduce leverage would be a downside catalyst; sustained deleveraging and margin improvement would challenge the underweight.